Quincy, MA (metropolitan Boston) LeukoLab facility serves as company’s second US-based hematologic tissue collection site, increasing assurance of supply and accelerating delivery of fresh and frozen products to eastern region and global life science researchers. [Read more…]
Regeneus Finalizes Terms with AGC, $5.5M Plus Future Payments of $11M
Regeneus receives upfront payment of US$5.5m from AGC
Regeneus Ltd (ASX: RGS), a clinical stage regenerative medicine company, today announced it has received US$5.5m from AGC as an upfront payment for the exclusive rights to manufacture Progenza under the terms of the collaboration and licence announced on 29 December 2016.
Regeneus is expected to receive a further US$11m in specific development and approval milestone payments.
Regeneus will be entitled, through its 50 per cent interest in Regeneus Japan, to its share of upfront licence fees, milestone payments and royalties from sub licensing the development and commercialisation of Progenza for osteoarthritis and all other clinical indications in Japan. [Read more…]
Cynata Inks Deal with FUJIFILM, $3.97M Plus Potential Payments of $60M+
Cynata and FUJIFILM Sign Development and Commercialisation Partnership Agreement
- Fujifilm takes A$3.97 million strategic equity stake in Cynata
- Parties to collaborate on the further development and commercialisation of Cynata’s lead Cymerus™ therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD)
- Potential future upfront and milestone payments in excess of A$60 million
- Double-digit royalties on CYP-001 product net sales
- Strategic relationship for potential future manufacture of CYP-001 and certain rights to other Cynata technology
StemBioSys Partners with VWR for U.S. and Canadian Distribution
SAN ANTONIO – StemBioSys Inc. announced today that it has entered into an agreement with VWR (NASDAQ: VWR) to distribute and market StemBioSys products.
VWR, the leading global independent provider of product and service solutions to laboratory and production facilities, will be the exclusive distributor for StemBioSys in both the United States and Canada. [Read more…]
NIMGenetics, Turnkey Solutions for Genomic Stability and Identity Requirements
NIMGenetics, founded in 2008, is an innovative, privately owned, European company specialized in the design and commercialization of high-performance products and services for genetic diagnosis.
Headquartered in Madrid, Spain, its scientific-medical team is professionally and scientifically accredited by the Spanish Association of Human Genetics, specializing in the development and application of high resolution genomic systems for reliable and accurate clinical diagnosis.
In addition to its scientific staff releasing more than 300 international publications in the field of human genetics and molecular biology, NIMGenetics’ Analytical Diagnostic Center with Genetics unit has been authorized by the Regional Ministry of Health of the Community of Madrid Spain.
At present, more than 50 diagnostic centers, clinics and hospitals use its services, with this number expanding on a year-over-year basis. [Read more…]
- « Previous Page
- 1
- …
- 229
- 230
- 231
- 232
- 233
- …
- 314
- Next Page »